Benzinga | Jun 3, 2021 08:01AM EDT

Rain Therapeutics Reports Collaboration With Tempus For Genomic Analysis in Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32

Clinical trial for MDM2 amplified cancers expected to commence in second half of 2021

NEWARK, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announced a master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing artificial intelligence and precision medicine company Tempus' genomic analysis platform. Under the terms of the agreement, Tempus will provide both centralized tumor testing and patient matching services using their Connect & TIME Trial(r) Network for the planned Phase 2 MDM2-amplified tumor-agnostic basket trial for RAIN-32, an oral MDM2 inhibitor in patients with certain solid tumors with pre-specified MDM2 amplification levels and wild type p53. The study is expected to commence in the second half of 2021.

"We are excited to enhance our tumor agnostic, MDM2-amplified basket trial strategy through this collaboration with Tempus, a company that shares our patient-centric mission," said Robert Doebele, M.D., Ph.D., cofounder and chief scientific officer at Rain Therapeutics. "Tempus' suite of DNA- and RNA-based tumor sequencing capabilities, including Tempus|xT and Tempus|xE, and comprehensive tumor profiling tests for solid tumors, will be invaluable as we seek to genetically identify and enroll patients with MDM2-dependent tumors in our novel Phase 2 basket trial evaluating RAIN-32."

"Roughly two-thirds of the U.S. population is located within 100 miles of an active TIME Trial site, giving patients access to genomically matched clinical trials with cutting-edge investigative therapies closer to home," said Dr. Kimberly Blackwell, Chief Medical Officer at Tempus. "We look forward to collaborating with Rain Therapeutics on their exciting Phase 2 asset, RAIN-32, and making this trial option available to patients facing MDM2-amplified cancer."